Seeking Alpha Publication Summary The recent two hurricanes devastated Texas and Florida causing some companies impacted negatively and some others positively. These companies can be identified systematically and quickly by sifting through their sector classification and supply chain network. Then pinpoint ETFs that are comprised mostly of these relevant companies to take positions on. I just … Continue reading Take Positions In These Three ETFs After Hurricane Harvey And Irma
Seeking Alpha Publication Summary More disruptions and innovations are needed in creating bond ETFs. Existing smart beta and factor-based bond ETFs show varied track records. We want a deep understanding of how these ETFs are designed. We also want to look into their past performances. ANGL is solid on both counts, but PHB presents a lousy … Continue reading Why I Favor ANGL, Dislike PHB
Seeking Alpha Publication Summary Both LQD and HYG are corporate bond ETFs issued by BlackRock. Past performance indicates LQD delivers a better return/risk profile than HYG. Dissecting the two indexes underneath these two funds reveals the fundamental reasons. Compared to Treasury ETFs, corporate bond ETFs usually offer higher returns to investors. For those with a better … Continue reading Both Are Corporate Bond ETFs, Why LQD Is Better Than HYG
Seeking Alpha Publication Summary Momentum Strategy works well in a bullish market. There are a handful Momentum ETFs for investors to use as investment vehicles. Understanding the underlying index strategies help investors make the right choice. MTUM is preferential because of its large AuM, low expense ratio, transparent methodology and sound track record. Momentum, by … Continue reading MTUM And PDP: Momentum ETFs And Their Underlying Indexes
Seeking Alpha Publication Summary LDOS may likely suffer a short term decline in the coming days. The shareholder converted from LMT will sell for quick profits. Similar transaction between WY and TPH can be referenced. In my preceding article - "Arbitrage Opportunities In Lockheed Martin And Leidos Split-Off Transaction", I expressed my long-term bullish view … Continue reading Will Leidos Take A Short-Term Hit After The Lockheed-Martin Split-Off?
Seeking Alpha Publication Summary Risk-free arbitrage opportunities do exist via public information sources. Only a simple English interpretation and arithmetic calculation are required to take advantage of this opportunity. Optimistic outlooks for both stocks are anticipated post-split-off. In a July 11 press release, Lockheed Martin (NYSE:LMT) announced that it will split off its Information Systems & Global … Continue reading Arbitrage Opportunities In Lockheed Martin And Leidos Split-Off Transaction
Trace the publication on Seeking Alpha: here Summary Allocating a proportion of investment capital into risky assets is necessary strategy in a comprehensive life financial plan. Seattle Genetics, Inc. (NASDAQ: SGEN) is one of these good bets. Unmet medical needs are heavily relying on targeted biotechnology treatments . SGEN offers enormous upside potential because of … Continue reading Seattle Genetics: Now Is A Good Time To Buy
Trace the publication on Seeking Alpha: here There was a contrarian article by Biotech Sage on Seeking Alpha early last Friday afternoon, jarring the InVivo (NASDAQ:NVIV) investor community. At first glance, I deemed it a convincing case even though the words are poignant and emotional. Later on, after poring over the evidence listed by the … Continue reading InVivo Therapeutics – Reality Distortion Or Reformation?
Trace the publication on Seeking Alpha: here I regard InVivo Therapeutics Holdings Corp (NASDAQ:NVIV) as a good investment in a short time horizon. Some of the key positive aspects of its business are in the following. 1. Market potential. InVivo was founded to develop a groundbreaking medical technology to treat Spinal Cord Injuries (SCI), for which there is no effective treatment … Continue reading InVivo Therapeutics Holdings Might Be Roaring In The Next Year
Trace the original publication in Seeking Alpha - here This company took a big hit when it failed its first attempt to get its weight management drug candidate Lorcaserin approved by the Food and Drug Administration (FDA). In December 2009, the New Drug Application (NDA) was submitted to the FDA and in October 2010, the … Continue reading Arena Faces Slim Chances Of Approval For Weight Drug